{"organizations": [], "uuid": "38bd0721bfe00d15627781b42b459aea1b02551b", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/brief-cytomx-therapeutics-provides-opera/brief-cytomx-therapeutics-provides-operational-update-idUSASB0C9AX", "country": "US", "domain_rank": 408, "title": "BRIEF-Cytomx Therapeutics Provides Operational Update", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-03-08T00:14:00.000+02:00", "replies_count": 0, "uuid": "38bd0721bfe00d15627781b42b459aea1b02551b"}, "author": "", "url": "https://www.reuters.com/article/brief-cytomx-therapeutics-provides-opera/brief-cytomx-therapeutics-provides-operational-update-idUSASB0C9AX", "ord_in_thread": 0, "title": "BRIEF-Cytomx Therapeutics Provides Operational Update", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "cytomx therapeutics inc", "sentiment": "none"}, {"name": "pfizer", "sentiment": "none"}, {"name": "reuters", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "March 7 (Reuters) - Cytomx Therapeutics Inc:\n* CYTOMX THERAPEUTICS ANNOUNCES FULL-YEAR 2017 FINANCIAL RESULTS AND PROVIDES OPERATIONAL UPDATE\n* CYTOMX THERAPEUTICS INC - COMPANY EXPECTS ITS EXISTING CAPITAL RESOURCES WILL BE SUFFICIENT TO FUND OPERATIONS INTO 2020\n* CYTOMX THERAPEUTICS - ON MARCH 6, CO RECEIVED NOTIFICATION OF PFIZERâ€™S INTENT TO TERMINATE THEIR 2013 RESEARCH COLLABORATION, OPTION, LICENSE AGREEMENT\n* CYTOMX THERAPEUTICS INC - NONE OF PROGRAMS IN PFIZER COLLABORATION HAD ADVANCED TO CLINICAL CANDIDATE STAGE Source text for Eikon: Further company coverage:\n ", "external_links": [], "published": "2018-03-08T00:14:00.000+02:00", "crawled": "2018-03-08T00:32:27.005+02:00", "highlightTitle": ""}